Plain-English translation of NCT06171750 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a new medication called (ANK-101) that is injected directly into tumors to treat advanced cancers. The study will first determine safe doses of the medication and how well patients tolerate it, then test whether combining it with another approved cancer drug works better for certain skin cancers. Researchers want to understand whether this direct-injection approach can help people whose cancers have stopped responding to standard treatments.
Many patients with advanced cancers run out of effective treatment options because their tumors become resistant to standard therapies. This medication is designed to work differently by boosting the body's immune system at the tumor site itself, offering hope for people who have exhausted other treatment choices.
You likely qualify if…
You likely don't qualify if…
You will receive injections of the medication directly into your tumor once every three weeks. Depending on which part of the trial you join, the injection may be into a tumor you can feel under the skin, or into a deeper tumor accessed with imaging guidance by a specialist. The study involves multiple visits for safety monitoring, blood tests, imaging scans, and tumor biopsies before and after treatment to measure how the medication is working. The total duration varies, but participants should expect ongoing visits over several months as researchers track your response and any side effects.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States
Canada